Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ)
Beijing, CN
Operating both domestically within the People's Republic of China and across international markets, Beijing SL Pharmaceutical Co., Ltd. is a biopharmaceutical firm dedicated to the research, development, manufacturing, and commercialization of genetic engineering-based pharmaceuticals and associated medicinal products. Its extensive portfolio of finished pharmaceutical products encompasses a diverse range of medications, including but not limited to, temozolomide, arsenic trioxide, lenalidomide, docetaxel, paclitaxel, recombinant human granulocyte colony-stimulating factor (filgrastim), recombinant human interleukin-11, recombinant human interleukin-2, thymopentin, vinorelbine bitartrate, hydroxyl-camptothecine, nimustine hydrochloride, asparaginase, PEG L-asparaginase, calcium foliate, recombinant human basic fibroblast growth factor, ciclosporin, mycophenolate mofetil dispersible, ornidazole, adefovir dipivoxil, levofloxacin hydrochloride, azithromycin, ribavirin, tenofovir disoproxil fumarate, valacylovir hydrochloride, lysozyme, stavudine, tropisetron hydrochloride, granisetron hydrochloride, omeprazole, ademetionine 1,4-butanedisulfonate, glutathione, enoxaparin sodium, coenzyme complex, ginkgo biloba extract, simvastatin, telmisartan, naftopidil, nicergoline, zaleplon, cytidine disodium triphosphate, febuxostat, risedronate sodium, loratadine dispersible, somatostatin, octreotide acetate, calcitonin (salmon), the combination of paracetamol and tramadol hydrochloride, and etodolac. Furthermore, the company supplies active pharmaceutical ingredients (APIs). Established in Beijing, People's Republic of China, in 1994, the enterprise initially operated under the name Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd. before officially adopting its current designation, Beijing SL Pharmaceutical Co., Ltd., in 1998.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.20% | -3.92% | -12.89% | -8.98% | -24.81% | -20.22% | -14.29% | -38.30% | -49.40% | -68.10% | +548.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-5.6% Q1'26: -19.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-385.7% Q1'26: -300.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+13.6% Q1'26: +47.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-0.4% Q1'26: +26.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-0.1% Q1'26: +3.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-3.5% ★ Q1'26: -6.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.16× ★ Q1'26: 0.12× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
622.77M
est: 622.77M (+0.0%)
|
1.01B
est: 1.01B (0.0%)
|
1.16B
est: 1.15B (+0.4%)
|
1.01B
est: 1.02B (-1.3%)
|
1.24B
est: 1.12B (+10.4%)
|
2.17B
est: 1.93B (+12.2%)
|
2.03B
est: 2.36B (-14.1%)
|
1.11B
est: 2.54B (-56.1%)
|
1.21B
est: 3.04B (-60.1%)
|
1.05B
est: 3.35B (-68.6%)
|
| EBITDA |
383.59M
est: 168.05M (+128.3%)
|
537.43M
est: 271.74M (+97.8%)
|
607.93M
est: 310.98M (+95.5%)
|
487.76M
est: 276.23M (+76.6%)
|
410.49M
est: 303.49M (+35.3%)
|
717.25M
est: 521.34M (+37.6%)
|
535.86M
est: 637.33M (-15.9%)
|
239.44M
est: 684.63M (-65.0%)
|
311.97M
est: 821.55M (-62.0%)
|
257.17M
est: 903.71M (-71.5%)
|
| EBIT |
365.99M
est: 87.72M (+317.2%)
|
517.10M
est: 141.85M (+264.5%)
|
575.18M
est: 162.33M (+254.3%)
|
454.18M
est: 144.19M (+215.0%)
|
373.00M
est: 158.43M (+135.4%)
|
661.45M
est: 272.14M (+143.1%)
|
459.26M
est: 332.69M (+38.0%)
|
149.95M
est: 357.38M (-58.0%)
|
212.30M
est: 428.86M (-50.5%)
|
143.66M
est: 471.75M (-69.5%)
|
| Net Income |
523.34M
|
481.01M
|
575.05M
est: 628.73M (-8.5%)
|
452.11M
est: 881.73M (-48.7%)
|
533.58M
est: 448.36M (+19.0%)
|
571.45M
est: 712.88M (-19.8%)
|
486.78M
est: 878.92M (-44.6%)
|
364.71M
est: 645.63M (-43.5%)
|
425.94M
est: 753.16M (-43.4%)
|
234.40M
est: 824.35M (-71.6%)
|
| SGA |
21.98M
est: 289.37M (-92.4%)
|
135.50M
est: 467.92M (-71.0%)
|
165.55M
est: 535.49M (-69.1%)
|
178.36M
est: 475.64M (-62.5%)
|
406.65M
est: 522.60M (-22.2%)
|
964.82M
est: 897.71M (+7.5%)
|
985.71M
est: 1.10B (-10.2%)
|
588.56M
est: 1.18B (-50.1%)
|
585.32M
est: 1.41B (-58.6%)
|
546.76M
est: 1.56B (-64.9%)
|
| EPS |
0.51
|
0.47
|
0.56
est: 0.59 (-5.8%)
|
0.44
est: 0.83 (-47.2%)
|
0.52
est: 0.42 (+22.7%)
|
0.83
est: 0.67 (+23.2%)
|
0.47
est: 0.83 (-43.4%)
|
0.36
est: 0.61 (-41.8%)
|
0.41
est: 0.71 (-41.8%)
|
0.23
est: 0.78 (-70.7%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-25 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-14 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P China ETF GXC | 0.01% | 42.9K | 0.59% |
| 2 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.00% | 20.7K | 0.49% |
| 3 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 569.0K | 0.07% |
| 4 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 243.1K | 0.06% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 113.6K | 0.39% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 57.7K | 0.29% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 7.7K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 17.3K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 852.8K | 0.06% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 44.4K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Li Ji | Accounting Supervisor & Financial Manager | — | female |
| Mingbo Xu | Founder, Non-Independent Chairman & GM | — | — |
| Shujie Liang | Secretary & Non-Independent Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002038.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
